57 related articles for article (PubMed ID: 21518812)
1. New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?
Fjell AM; Walhovd KB
Neuroscientist; 2011 Oct; 17(5):592-605. PubMed ID: 21518812
[TBL] [Abstract][Full Text] [Related]
2. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
Schmand B; Huizenga HM; van Gool WA
Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
[TBL] [Abstract][Full Text] [Related]
4. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
7. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
8. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
10. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
[TBL] [Abstract][Full Text] [Related]
11. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
Sluimer JD; Bouwman FH; Vrenken H; Blankenstein MA; Barkhof F; van der Flier WM; Scheltens P
Neurobiol Aging; 2010 May; 31(5):758-64. PubMed ID: 18692273
[TBL] [Abstract][Full Text] [Related]
12. [Biomarkers in spinal fluid of patients with dementia].
Skogseth RE; Fladby T; Mulugeta E; Aarsland D
Tidsskr Nor Laegeforen; 2011 Nov; 131(22):2235-8. PubMed ID: 22085948
[TBL] [Abstract][Full Text] [Related]
13. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.
Solé-Padullés C; Lladó A; Bartrés-Faz D; Fortea J; Sánchez-Valle R; Bosch B; Antonell A; Molinuevo JL; Rami L
Psychiatry Res; 2011 Jun; 192(3):140-6. PubMed ID: 21546220
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients.
Kandimalla RJ; S P; Bk B; Wani WY; Sharma DR; Grover VK; Bhardwaj N; Jain K; Gill KD
Neurosci Lett; 2011 Jan; 487(2):134-8. PubMed ID: 20599474
[TBL] [Abstract][Full Text] [Related]
16. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
17. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
[TBL] [Abstract][Full Text] [Related]
18. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
[TBL] [Abstract][Full Text] [Related]
20. A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease.
Serot JM; Zmudka J; Jouanny P
J Alzheimers Dis; 2012; 30(1):17-26. PubMed ID: 22349684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
